Prospective, Real-Life Evaluation of a Low-Angle Arterial Entry Closure Device for Endovascular, Outpatient-Based Interventions Using the Arstasis AXERAandreg; 2 System (AXCELERATE Trial)
Conclusions: The AXCELERATE trial shows that the use of the AXERA® 2 device reduces TTS, TTA and TTD, while being a safe and effective method of hemostasis for outpatient-based

